Prince Mohammad Bin Fahd University, PO Box 1664, Al Khobar, 31952, Kingdom of Saudi Arabia.
Pharmacol Rep. 2020 Dec;72(6):1542-1552. doi: 10.1007/s43440-020-00175-2. Epub 2020 Oct 27.
The pandemic of SARS CoV-2 has required urgent medical treatments for numerous patients. As no specific antiviral agents were available, different off-the-shelf alternatives have been explored.
Here, we review the rationale behind the use of Favipiravir, and report of the specific studies supporting this treatment being conducted.
Here we analyze the relevant literature to conclude about the present opportunities offered by this therapeutic agent.
This antiviral drug approved influenza in Japan since 2014, has a demonstrated in vitro activity against SARS CoV-2 and is being investigated in several trials for SARS CoV-2. Signals of benefit were shown in a small trial for SARS CoV-2. However, in another small study, there was no advantage.
Further studies, statistically more significant, are urgently needed to understand the best opportunities offered by this treatment.
SARS-CoV-2 的大流行需要对众多患者进行紧急治疗。由于没有特定的抗病毒药物，因此已经探索了不同的现成替代品。
在这里，我们回顾了使用法匹拉韦的基本原理，并报告了支持这种治疗方法的具体研究。
在这里，我们分析相关文献，以得出该治疗药物目前提供的机会的结论。
自 2014 年以来，这种在日本被批准用于流感的抗病毒药物，已被证明具有针对 SARS-CoV-2 的体外活性，并且正在针对 SARS-CoV-2 进行多项试验。一项针对 SARS-CoV-2 的小型试验显示出了有益的信号。但是，在另一项小型研究中，没有优势。
迫切需要进行更多具有统计学意义的进一步研究，以了解这种治疗方法带来的最佳机会。
